Two Sigma Advisers
DAWN

Two Sigma Advisers’s Day One Biopharmaceuticals DAWN Stock Holding History

Two Sigma Advisers’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,800
Closed -$102K – 2366
2025
Q1 		$102K Sell
12,800
-93,800
-88% -$1.01M ﹤0.01% 2240
2024
Q4 		$1.35M Sell
106,600
-8,500
-7% -$118K ﹤0.01% 1319
2024
Q3 		$1.6M Buy
115,100
+30,800
+37% +$439K ﹤0.01% 1189
2024
Q2 		$1.16M Buy
+84,300
New +$1.23M ﹤0.01% 1475
2023
Q3 		– Sell
-16,400
Closed -$196K – 2430
2023
Q2 		$196K Buy
+16,400
New +$214K ﹤0.01% 2105
2022
Q2 		– Sell
-19,900
Closed -$197K – 2703
2022
Q1 		$197K Buy
+19,900
New +$263K ﹤0.01% 2386

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's DAWN Position: Q2 2025 in Review

Two Sigma Advisers sold out of Day One Biopharmaceuticals (DAWN) in Q2 2025, closing a stake of 12,800 shares — an estimated $102K sold.

Two Sigma Advisers first reported a position in DAWN in Q1 2022 and held it in 6 quarters. The position peaked at $1.6M in Q3 2024. 174 funds tracked by Wall St. Rank hold DAWN as of Q2 2025.

  • Two Sigma Advisers reported no remaining Day One Biopharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 12,800 Day One Biopharmaceuticals shares in Q2 2025, an estimated $102K.
  • Two Sigma Advisers first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 6 quarters.
  • Two Sigma Advisers's Day One Biopharmaceuticals position peaked at $1.6M in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2025.

Based on Two Sigma Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.